| 万明宇,马晓露,丁永锋,等.晚期胃癌免疫治疗现状和临床研究进展[J].肿瘤学杂志,2023,29(6):459-469. |
| 晚期胃癌免疫治疗现状和临床研究进展 |
| Current Status and Research Progress of Immunotherapy for Advanced Gastric Cancer |
| 投稿时间：2023-01-04 |
| DOI：10.11735/j.issn.1671-170X.2023.06.B004 |
|
 |
| 中文关键词: 胃肿瘤 免疫疗法 免疫检查点抑制剂 临床研究 |
| 英文关键词:gastric cancer immunotherapy immune checkpoint inhibitors clinical trials |
| 基金项目:浙江省自然科学基金（LQ19H160031，LQ20H160028） |
|
| 摘要点击次数: 486 |
| 全文下载次数: 184 |
| 中文摘要: |
| 摘 要：胃癌是常见的消化道恶性肿瘤，2020年新增病例数108.9万例，居第5位，死亡约76.9万例，居第4位，中国胃癌发病和死亡占全球40%以上。晚期胃癌5年生存率低，以往单纯化疗中位生存期不超过1年。以免疫检查点抑制剂为代表的免疫治疗改变了晚期胃癌系统治疗的格局，其可改善患者的预后及生存质量，突破治疗瓶颈，线数前移逐渐成为一线标准治疗药物。随着免疫治疗的快速发展，各种免疫检查点抑制剂推陈出新或联合靶向治疗、化疗的新模式不断探索，是当前胃癌领域的研究热点。全文回顾了当前晚期胃癌免疫检查点抑制剂应用相关的临床研究结果，归纳总结了当前免疫治疗现状及面临的挑战，以期为临床决策和未来临床研究提供参考。 |
| 英文摘要: |
| Abstract： Gastric cancer is a common malignant tumor of the digestive system. In 2020， the number of new cases was 1.089 million， ranking fifth of all malignant tumors， and the number of deaths was about 769 000， ranking fourth of all cancer deaths worldwide. The incidence and deaths of gastric cancer in China account for more than 40% of the sum of whole world. The 5-year survival rate of advanced gastric cancer remains low， the median survival time of chemothe-rapy alone was less than 1 year. Immunotherapy， in particular， the immune checkpoint inhibitors， has changed the pattern of treatment and improved the quality of life of patients with advanced gastric cancer， becoming the new standard of first-line treatment. Various immune checkpoint inhibitors have emerged and new combined treatment has also been explored， which is a hotspot in the field of gastric cancer. This paper reviews the current status and research progress of immune checkpoint inhibitor therapy， and discusses the challenge of immunotherapy in advanced gastric cancer to provide an option for clinical application and future clinical studies. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |